Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly
GILD Gilead Sciences, Inc. weekly Stock Chart
GILD [NASD]
Gilead Sciences, Inc.
Healthcare | Drug Manufacturers - Major | USA
statements
IndexS&P 500 P/E14.09 EPS (ttm)4.63 Insider Own0.70% Shs Outstand1.27B Perf Week3.11%
Market Cap82.84B Forward P/E9.37 EPS next Y6.96 Insider Trans-0.41% Shs Float1.26B Perf Month-0.75%
Income5.97B PEG6.17 EPS next Q1.74 Inst Own83.30% Short Float1.11% Perf Quarter0.29%
Sales22.36B P/S3.71 EPS this Y-45.60% Inst Trans0.17% Short Ratio2.34 Perf Half Y3.62%
Book/sh17.81 P/B3.66 EPS next Y-0.84% ROA9.40% Target Price80.45 Perf Year-14.52%
Cash/sh21.40 P/C3.05 EPS next 5Y2.29% ROE26.80% 52W Range60.32 - 76.29 Perf YTD4.28%
Dividend2.52 P/FCF19.31 EPS past 5Y18.10% ROI12.00% 52W High-14.50% Beta1.09
Dividend %3.86% Quick Ratio3.70 Sales past 5Y14.60% Gross Margin79.40% 52W Low8.14% ATR1.19
Employees11000 Current Ratio3.80 Sales Q/Q0.70% Oper. Margin37.70% RSI (14)58.18 Volatility1.53% 1.81%
OptionableYes Debt/Eq1.15 EPS Q/Q6.60% Profit Margin26.60% Rel Volume0.79 Prev Close65.35
ShortableYes LT Debt/Eq1.06 EarningsOct 24 AMC Payout51.60% Avg Volume5.95M Price65.23
Recom2.10 SMA202.33% SMA501.63% SMA200-0.72% Volume4,682,588 Change-0.18%
Oct-17-19Resumed BofA/Merrill Neutral $70
Jul-29-19Upgrade RBC Capital Mkts Outperform → Top Pick $91
Jul-15-19Upgrade Wells Fargo Market Perform → Outperform $68 → $88
May-28-19Downgrade Goldman Neutral → Sell
May-23-19Upgrade Citigroup Neutral → Buy
May-21-19Initiated Credit Suisse Neutral $70
Apr-26-19Initiated Bernstein Outperform $82
Apr-10-19Upgrade UBS Neutral → Buy $75 → $77
Feb-12-19Downgrade Wells Fargo Outperform → Market Perform $95 → $68
Feb-12-19Downgrade Citigroup Buy → Neutral $100 → $75
Jan-03-19Upgrade Oppenheimer Perform → Outperform $85
Oct-26-18Reiterated Barclays Overweight $90 → $95
Oct-26-18Downgrade Piper Jaffray Overweight → Neutral
Oct-01-18Initiated Cantor Fitzgerald Overweight $87
Jul-26-18Downgrade Robert W. Baird Outperform → Neutral $79
Jun-28-18Initiated Raymond James Strong Buy
May-02-18Reiterated Maxim Group Buy $94 → $89
Mar-06-18Reiterated Barclays Overweight $90 → $95
Feb-22-18Reiterated Leerink Partners Mkt Perform $83 → $80
Feb-12-18Reiterated Mizuho Buy $83 → $95
Oct-17-19 05:45PM  Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know Zacks
03:42PM  Job hopping: This is how long employees typically stay at Tesla, Apple, Facebook, Cisco, Nvidia, Oracle and more American City Business Journals
10:54AM  Can New Drugs Help Lilly (LLY) to Deliver Solid Q3 Earnings? Zacks
10:34AM  Gilead Sciences (GILD) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Zacks
Oct-16-19 09:17AM  Biogen (BIIB) to Report Q3 Earnings: What's in the Cards? Zacks
01:35AM  PRESS DIGEST - Wall Street Journal - Oct 16 Reuters
Oct-15-19 03:26PM  Gilead Just Named a New CFO. Is More Deal Making on the Way? Barrons.com
11:57AM  The Zacks Analyst Blog Highlights: Cisco Systems, SAP, Gilead Sciences, Bank of America and Caterpillar Zacks
08:48AM  Gilead names Andrew Dickinson CFO effective Nov. 1 MarketWatch
08:30AM  Gilead Sciences Appoints Andrew Dickinson as Chief Financial Officer Business Wire
Oct-14-19 02:49PM  Top Stock Reports for Cisco, SAP & Gilead Zacks
09:14AM  Why cell therapies are cancer's next frontier American City Business Journals
Oct-11-19 05:45PM  Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know Zacks
05:10PM  Startup with eye on fatty liver disease NASH lays out $70M IPO plan American City Business Journals
12:49PM  Jazz Starts CAR T-cell Linked Neurotoxicity Study Enrollment Zacks
10:10AM  Why Gilead (GILD) Could Beat Earnings Estimates Again Zacks
09:19AM  Gilead-Galapagos Report Efficacy & Safety Results on RA Drug Zacks
08:14AM  The Daily Biotech Pulse: Therapix Extends Merger Deadline, Five Prime Restructures, Gilead-Galapagos Rheumatism Drug Readout Benzinga
Oct-10-19 06:00PM  Gilead and Galapagos Announce Efficacy and Safety Results of Filgotinib Through 52 Weeks in FINCH 1 and FINCH 3 Studies in Rheumatoid Arthritis Business Wire
04:05PM  Gilead Sciences to Release Third Quarter 2019 Financial Results on Thursday, October 24, 2019 Business Wire
Oct-09-19 06:39PM  Do Hedge Funds Love Gilead Sciences, Inc. (GILD)? Insider Monkey
11:18AM  Biotech Stock Roundup: GILD's Descovy Label Expansion Gets FDA Nod & Other Updates Zacks
11:10AM  Gilead (GILD) Files NDA for RA Candidate Filgotinib in Japan Zacks
Oct-08-19 11:43AM  UPDATE 2-Humira, Rituxan top list of U.S. drugs with biggest price increases -report Reuters
08:27AM  REFILE-UPDATE 1-Humira, Rituxan top list of U.S. drugs with biggest price increases -report Reuters
08:00AM  REFILE-Humira, Rituxan top list of U.S. costliest drug price increases -report Reuters
07:11AM  The Daily Biotech Pulse: D-Day For Clinuvel, Qiagen Warns Of Q3 Shortfall, Prevail Announces Gene Therapy Collaboration Benzinga
02:00AM  Gilead Sciences Submits New Drug Application for Filgotinib for the Treatment of Adults With Rheumatoid Arthritis in Japan Business Wire
Oct-07-19 09:08AM  Novo Nordisk Focuses on Pipeline Development Amid Competition Zacks
08:40AM  Gilead Sciences names chief medical officer, from Genentech MarketWatch
08:30AM  Gilead Sciences Appoints Merdad Parsey, MD, PhD as Chief Medical Officer Business Wire
Oct-04-19 10:45AM  Gilead's Descovy HIV Regimen Gets FDA Nod for Label Expansion Zacks
10:00AM  Gilead Stock Is Among The Biggest Biotech Stocks But Should You Buy It? Investor's Business Daily
08:30AM  Gilead Presents New Data From the Companys HIV Clinical Development Program and Latest Findings on the Impact of HIV Pre-exposure Prophylaxis (PrEP) at IDWeek 2019 Business Wire
Oct-03-19 05:59PM  UPDATE 1-U.S. FDA approves Gilead's Descovy for HIV prevention Reuters
05:50PM  Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know Zacks
03:32PM  U.S. FDA approves Gilead's HIV prevention treatment Reuters
02:49PM  U.S. Food and Drug Administration Approves Descovy® for HIV Pre-Exposure Prophylaxis (PrEP) Business Wire
Oct-01-19 02:59PM  Forget FAANG, investors should consider MANG Yahoo Finance
08:00AM  Looking For Growth? Take A Look At These Biotechnology Stocks Investor's Business Daily
07:36AM  Did You Manage To Avoid Gilead Sciences's (NASDAQ:GILD) 40% Share Price Drop? Simply Wall St.
Sep-30-19 02:52PM  Investors flee Biotech ETFs as they Lag Bull Market Investopedia
12:38PM  Ariel Investments' Rupal Bhansali: Growth is working, but it's time to switch to value' Yahoo Finance Video
Sep-29-19 09:15PM  Stocks That Fell to 3-Year Lows in the Week of Sept. 27 GuruFocus.com
Sep-27-19 05:38PM  AbbVie (ABBV) Gets FDA Nod for Label Expansion of HCV Drug Zacks
Sep-26-19 11:40AM  Enanta's Stock Down Despite NASH Drug Meeting Goal in Study Zacks
Sep-25-19 05:45PM  Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know Zacks
Sep-24-19 08:49AM  3 Big Stock Charts for Tuesday: Baker Hughes, Gilead Sciences and Jefferies Financial Group InvestorPlace
Sep-23-19 12:42PM  Novo Nordisk's Semaglutide in Tablet Form Gets FDA Approval Zacks
11:01AM  Merck's Two HIV Drugs Get FDA Approval for Expanded Use Zacks
Sep-20-19 01:10PM  Gilead, AbbVie Are Innovative, but May Be Underappreciated GuruFocus.com
11:04AM  Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? Zacks
Sep-18-19 05:14PM  5 Predictable Guru Stocks GuruFocus.com
02:10PM  Highest paying U.S. jobs and companies ranked Yahoo Finance Video
12:00AM  These are the highest paying companies, according to Glassdoor Yahoo Finance
Sep-17-19 05:45PM  Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know Zacks
01:00AM  Our Ultimate Stock-Pickers' Top 10 Dividend-Yielding Stocks Morningstar
Sep-15-19 08:45AM  Goldman Sachs: 3 Large-Cap Stocks To Sell Now TipRanks
Sep-13-19 08:29AM  A Cheap Biotech Stock With a Novel Treatment for Multiple Sclerosis Barrons.com
Sep-12-19 05:46PM  Gilead Tops List of Most Innovative Drug Companies GuruFocus.com
01:55PM  5 Companies Growing Earnings GuruFocus.com
Sep-11-19 05:45PM  Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know Zacks
07:15AM  NASDAQ: GILD Investor Notice: Lawsuit by Consumers against Gilead Sciences, Inc. announced by Shareholders Foundation ACCESSWIRE
Sep-10-19 01:02PM  Peninsula startup with connections to Gilead snags $34M with new approach to mend torn genes American City Business Journals
Sep-09-19 11:50PM  The Testaments by Margaret Atwood struggles to live up to its lauded prequel Financial Times
07:30AM  Gilead Sciences and the Elton John AIDS Foundation Launch RADIAN Initiative to Address HIV in Eastern Europe and Central Asia (EECA) Business Wire
Sep-08-19 08:31AM  Gilead Sciences, Inc. (NASDAQ:GILD)'s Could Be A Buy For Its Upcoming Dividend Simply Wall St.
Sep-05-19 05:45PM  Gilead Sciences (GILD) Gains But Lags Market: What You Should Know Zacks
Sep-03-19 05:46PM  Top-Performing Biotech ETFs YTD Zacks
Sep-02-19 10:59AM  Gilead Sciences (NASDAQ:GILD) Has A Pretty Healthy Balance Sheet Simply Wall St.
Sep-01-19 07:30AM  3 High-Yield Dividend Stocks to Buy on Sale Motley Fool
07:00AM  Better Buy: Gilead Sciences vs. Biogen Motley Fool
Aug-30-19 05:45PM  Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know Zacks
Aug-29-19 09:31AM  Why Is Gilead (GILD) Down 2.9% Since Last Earnings Report? Zacks
Aug-28-19 03:45PM  UPDATE 1-FDA flags risks from AbbVie, Gilead, Merck hepatitis C drugs to certain patients Reuters
03:25PM  FDA flags serious risks with hepatitis C drugs from AbbVie, Gilead and Merck Reuters
10:34AM  Biotech Stock Roundup: AMGN to Buy CELG's Otezla, ALXN's Soliris Gets EC Nod & More Zacks
Aug-26-19 04:34PM  Gilead Sciences to Present at the Morgan Stanley Global Healthcare Conference on Tuesday, September 10 Business Wire
11:54AM  Alberta Provides Access to Biktarvy® for the Treatment of HIV CNW Group
08:28AM  Gilead & Galapagos Close Research & Development Agreement Zacks
08:22AM  3 Big Stock Charts for Monday: Intuit, Gilead Sciences and Nike InvestorPlace
Aug-23-19 04:01PM  Gilead and Galapagos Complete Closing of Their Transformative Research and Development Collaboration Business Wire
07:33AM  The Zacks Analyst Blog Highlights: Union Pacific, Lowe's, Gilead, Target and Emerson Zacks
Aug-22-19 02:37PM  Novo Nordisk's Fiasp Gets EC Approval for Label Expansion Zacks
02:33PM  Top Research Reports for Union Pacific, Lowe's & Gilead Zacks
11:55AM  The Zacks Analyst Blog Highlights: Celgene, Gilead, Vertex, Sarepta and Regeneron Zacks
Aug-21-19 11:00AM  Biotech Stock Roundup: CELG's Inrebic Gets FDA Nod, SRPT Suffers Setback & More Zacks
03:57AM  Gilead to challenge US patents on HIV drug Truvada Financial Times
Aug-20-19 10:00AM  Flush with cash after Gilead deal, founder pivots to real estate for his companies American City Business Journals
10:00AM  DRRX: Gilead Agreement, Near-Term Value-Inflection Opportunities Make DRRX Particularly Attractive at Current Valuation Zacks Small Cap Research
Aug-19-19 01:50PM  5 Top ESG Stocks on RBC Capitalrsquo;s lsquo;Best Ideasrsquo; List Kiplinger
Aug-18-19 05:00AM  Gilead did not seek US exclusivity on PrEP with Truvada Financial Times
Aug-17-19 06:53PM  Stocks That Fell to 3-Year Lows in the Week of Aug. 16 GuruFocus.com
12:16PM  3 Dividend Stocks That Should Pay You the Rest of Your Life Motley Fool
Aug-16-19 09:19AM  Gilead's (GILD) Filgotinib MAA for RA Accepted in Europe Zacks
Aug-15-19 05:27PM  Frozen assets: How a startup wants to cryobank your cells to fight cancer in the future American City Business Journals
04:01PM  European Medicines Agency Validates Marketing Application for Filgotinib for the Treatment of Rheumatoid Arthritis Business Wire
08:00AM  Québec Provides Access to Biktarvy® for the Treatment of HIV CNW Group
Aug-14-19 09:21AM  Biotech Stock Roundup: Amgen's Enbrel Patent Win, AMRN's Setback & More Zacks
08:34AM  Zacks Industry Outlook Highlights: Gilead Sciences, Regeneron Pharmaceuticals, Amgen, Vertex Pharmaceuticals and Alexion Pharmaceuticals Zacks
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a kinase inhibitor; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and AmBisome, an antifungal agent to treat serious invasive fungal infections. In addition, the company offers its products under the name Cayston, Emtriva, Hepsera, Sovaldi, and Tybost. Further, it develops product candidates for the treatment of HIV/AIDS and liver diseases, hematology/oncology, inflammation/respiratory diseases, and others. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company; Janssen Sciences Ireland UC; Japan Tobacco Inc.; Scholar Rock Holding Corporation; Tango Therapeutics; National Cancer Institute; Pfizer, Inc.; Sangamo Therapeutics, Inc.; Gadeta B.V.; HiFiBiO Therapeutics; Agenus Inc.; HOOKIPA Pharma Inc.; Goldfinch Bio, Inc.; insitro Inc.; Nurix Therapeutics, Inc.; Lyndra Therapeutics; and Carna Biosciences Inc., as well as the Chengdu Hi-tech Zone. The company was founded in 1987 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lofton Kevin EDirectorOct 01Option Exercise0.0021,527064,859Oct 03 09:03 PM
WOLD OLSEN PERDirectorAug 28Option Exercise23.764,908116,590102,762Aug 29 04:42 PM
WOLD OLSEN PERDirectorAug 28Sale63.914,908313,67197,854Aug 29 04:42 PM
Pletcher Brett AEVP, Gen Counsel & Corp SecAug 19Sale64.3560839,12327,198Aug 20 03:13 PM
Pletcher Brett AEVP, Gen Counsel & Corp SecJul 23Option Exercise24.917,200179,31634,398Jul 25 06:37 PM
Pletcher Brett AEVP, Gen Counsel & Corp SecJul 23Sale65.077,200468,50427,198Jul 25 06:37 PM
Pletcher Brett AEVP, Gen Counsel & Corp SecJun 18Sale68.755,816399,85027,198Jun 20 04:52 PM
Cogan John FrancisDirectorMay 01Option Exercise22.022,86863,13957,728May 02 06:45 PM
Whitley Richard JamesDirectorMay 01Option Exercise22.029,534209,89134,669May 02 06:48 PM
Whitley Richard JamesDirectorMay 01Sale65.029,534619,93425,135May 02 06:48 PM
Cogan John FrancisDirectorMay 01Sale64.892,868186,11654,860May 02 06:45 PM
Cogan John FrancisDirectorApr 24Option Exercise22.022,70059,44157,560Apr 25 06:48 PM
Lofton Kevin EDirectorApr 24Option Exercise24.9113,208328,94543,332Apr 25 06:51 PM
Cogan John FrancisDirectorApr 24Sale62.612,700169,05454,860Apr 25 06:48 PM
Cogan John FrancisDirectorApr 17Option Exercise22.022,70059,44157,560Apr 18 07:04 PM
Cogan John FrancisDirectorApr 17Sale64.232,700173,42454,860Apr 18 07:04 PM
Cogan John FrancisDirectorApr 10Option Exercise22.022,70059,44157,560Apr 12 06:28 PM
Cogan John FrancisDirectorApr 10Sale67.232,700181,52154,860Apr 12 06:28 PM
Cogan John FrancisDirectorApr 03Option Exercise22.022,70059,44157,560Apr 04 07:31 PM
Cogan John FrancisDirectorApr 03Sale66.742,700180,19854,860Apr 04 07:31 PM
Whitley Richard JamesDirectorApr 01Option Exercise22.029,534209,89134,669Apr 02 08:10 PM
Whitley Richard JamesDirectorApr 01Sale65.489,534624,25525,135Apr 02 08:10 PM
Cogan John FrancisDirectorMar 27Option Exercise22.022,70059,44157,560Mar 28 06:09 PM
Cogan John FrancisDirectorMar 27Sale64.142,700173,17854,860Mar 28 06:09 PM
Cogan John FrancisDirectorMar 20Option Exercise22.022,70059,44157,560Mar 21 07:08 PM
Cogan John FrancisDirectorMar 20Sale65.072,700175,68954,860Mar 21 07:08 PM
WILSON GAYLE EDirectorFeb 19Option Exercise0.0019,0680143,567Feb 20 08:06 PM
WILSON GAYLE EDirectorFeb 19Sale67.0819,0681,279,074124,499Feb 20 08:06 PM
MARTIN JOHN CDirectorDec 03Option Exercise23.6050,0001,180,0002,927,762Dec 04 08:02 PM
MARTIN JOHN CDirectorDec 03Sale71.2050,0003,560,1782,877,762Dec 04 08:02 PM
MILLIGAN JOHN FPresident and CEONov 27Option Exercise23.60280,0006,608,0001,574,306Nov 29 08:42 PM
MARTIN JOHN CDirectorNov 01Option Exercise23.6050,0001,180,0003,067,762Nov 05 07:45 PM
MARTIN JOHN CDirectorNov 01Sale69.5550,0003,477,6173,017,762Nov 05 07:45 PM
open in yahoo | open in reuters | open in google